Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andriy Derkach

Showing results (51-60 of 135) with videos related to

Pageof 14
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 29, 2020
Association of Body Mass Index with Fecal Microbial Diversity and Metabolites in the Northern Finland Birth CohortErikka Loftfield, Karl-Heinz Herzig, J Gregory Caporaso, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 22, 2026
Diagnosis Disclosure and Related Illness Experience in Patients With Multiple Myeloma and Precursor Plasma Cell DisordersMaria A Malik, Akshay A Dalvi, Andriy Derkach, et al.
Journal of the American College of Emergency Physicians Open|March 5, 2026
Development and Validation of a Prognostic Risk Score for Patients With Cancer and Neutropenic Fever Presenting to the Emergency DepartmentSandy Nath, Aiham Qdaisat, Andriy Derkach, et al.
Blood Neoplasia|June 24, 2025
Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemiaKuo-Kai Chin, Yannis Valtis, Andriy Derkach, et al.
American Journal of Hematology|October 21, 2021
Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasmsAmber C King, Taylor M Weis, Andriy Derkach, et al.
Cancer Research|December 4, 2020
Patterns of Human Leukocyte Antigen Class I and Class II Associations and CancerZhiwei Liu, Andriy Derkach, Kelly J Yu, et al.
Leukemia & Lymphoma|October 14, 2024
HMA/VEN treatment modifications and associated outcomes in <i>IDH</i>-mutant AMLKuo-Kai Chin, Andriy Derkach, Christopher Famulare, et al.
International Journal of Radiation Oncology, Biology, Physics|February 28, 2026
Integrating genomic and non-genomic data to stratify the risk of contralateral breast cancer after radiotherapySangkyu Lee, Xiang Shu, Andriy Derkach, et al.
Leukemia & Lymphoma|October 26, 2022
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitorsJan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, et al.
Leukemia Research|September 15, 2022
Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclaxJan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, et al.
Pageof 14

Showing results (51-60 of 135) with videos related to

Sort By:
Pageof 14
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 29, 2020
Association of Body Mass Index with Fecal Microbial Diversity and Metabolites in the Northern Finland Birth CohortErikka Loftfield, Karl-Heinz Herzig, J Gregory Caporaso, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 22, 2026
Diagnosis Disclosure and Related Illness Experience in Patients With Multiple Myeloma and Precursor Plasma Cell DisordersMaria A Malik, Akshay A Dalvi, Andriy Derkach, et al.
Journal of the American College of Emergency Physicians Open|March 5, 2026
Development and Validation of a Prognostic Risk Score for Patients With Cancer and Neutropenic Fever Presenting to the Emergency DepartmentSandy Nath, Aiham Qdaisat, Andriy Derkach, et al.
Blood Neoplasia|June 24, 2025
Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemiaKuo-Kai Chin, Yannis Valtis, Andriy Derkach, et al.
American Journal of Hematology|October 21, 2021
Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasmsAmber C King, Taylor M Weis, Andriy Derkach, et al.
Cancer Research|December 4, 2020
Patterns of Human Leukocyte Antigen Class I and Class II Associations and CancerZhiwei Liu, Andriy Derkach, Kelly J Yu, et al.
Leukemia & Lymphoma|October 14, 2024
HMA/VEN treatment modifications and associated outcomes in <i>IDH</i>-mutant AMLKuo-Kai Chin, Andriy Derkach, Christopher Famulare, et al.
International Journal of Radiation Oncology, Biology, Physics|February 28, 2026
Integrating genomic and non-genomic data to stratify the risk of contralateral breast cancer after radiotherapySangkyu Lee, Xiang Shu, Andriy Derkach, et al.
Leukemia & Lymphoma|October 26, 2022
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitorsJan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, et al.
Leukemia Research|September 15, 2022
Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclaxJan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, et al.
Pageof 14